IXICO CEO on growth, margins & TechBio strategy

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden joined Proactive's Stephen Gunnion to discuss a strong first half, with revenues up 23% to £3.9 million and gross margin expanding to 53%. Growth has been driven by new contract wins, extensions and rising demand for analytics across late-stage Alzheimer's, Parkinson's and rare CNS trials. The order book hit a multi-year high of £18.1 million - up 38% - giving strong visibility on future revenues. Following a £10 million fundraise, IXICO is now pursuing a TechBio strategy, licensing its platform to unlock recurring revenue streams and building strategic partnerships, including a recent collaboration with Medidata. For more insights into IXICO’s growth strategy and future outlook, visit Proactive’s YouTube channel, like this video, subscribe, and turn on notifications so you never miss an update. #IXICO #BramGoorden #BiotechStocks #HealthcareTech #TechBio #ClinicalTrials #AlzheimersResearch #ParkinsonsResearch #CNS #Biomarkers #Medidata #Investing #SmallCapStocks #LifeSciences #StockMarketNews